Phase 3 Readout~month

Phase 3 Topline: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effica

Name: Phase 3 Topline: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effica
Start: 2034-01-01

January 1, 2034

Company: Solid Biosciences Inc. (SLDB)
Drug: duchenne
Indication: Duchenne Muscular Dystrophy

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar

Phase 3 Topline: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effica — SLDB Phase 3 Readout | BioSniper